Teva Pharmaceutical Industries Ltd. $TEVA is Clal Insurance Enterprises Holdings Ltd's 4th Largest Position
Clal Insurance reduced its stake in Teva Pharmaceutical by 14.5% in Q2, owning 32.36M shares worth $543M. Teva's stock is Clal's 4th largest position. Other investors adjusted their holdings, with hedge funds owning 54.05% of Teva's stock. Teva's Q3 earnings beat estimates, reporting $0.78 EPS and $4.48B revenue. Analysts raised price targets, with JPMorgan setting $28.00. Insider Roberto Mignone sold 200,000 shares. Teva's stock opened at $24.86, with a market cap of $28.51B.
Clal Insurance Enterprises Holdings Ltd lowered its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 14.5% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 32,362,683 shares of the company's stock after selling 5,491,385 shares during the quarter. Teva Pharmaceutical Industries makes up about 5.3% of Clal Insurance Enterprises Holdings Ltd's holdings, making the stock its 4th biggest position. Clal Insurance Enterprises Holdings Ltd owned about 2.82% of Teva Pharmaceutical Industries worth $543,026,000 as of its most recent filing with the SEC.
- MarketBeat Week in Review – 02/03 - 02/07
Several other hedge funds also recently bought and sold shares of TEVA. Bourgeon Capital Management LLC increased its position in Teva Pharmaceutical Industries by 100.7% during the 2nd quarter. Bourgeon Capital Management LLC now owns 723,974 shares of the company's stock worth $12,134,000 after purchasing an additional 363,252 shares in the last quarter. Amundi boosted its stake in shares of Teva Pharmaceutical Industries by 18.5% during the 1st quarter. Amundi now owns 678,758 shares of the company's stock worth $10,080,000 after purchasing an additional 105,846 shares during the last quarter. IFM Investors Pty Ltd grew its holdings in shares of Teva Pharmaceutical Industries by 9.4% during the second quarter. IFM Investors Pty Ltd now owns 226,534 shares of the company's stock worth $3,797,000 after buying an additional 19,447 shares in the last quarter. Jump Financial LLC raised its position in shares of Teva Pharmaceutical Industries by 172.1% in the first quarter. Jump Financial LLC now owns 1,325,526 shares of the company's stock valued at $20,373,000 after buying an additional 838,423 shares during the last quarter. Finally, Financial Sense Advisors Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 63.5% during the first quarter. Financial Sense Advisors Inc. now owns 405,421 shares of the company's stock valued at $6,231,000 after buying an additional 157,421 shares during the period. Hedge funds and other institutional investors own 54.05% of the company's stock.
Teva Pharmaceutical Industries Trading Up 1.1%
TEVA stock opened at $24.86 on Wednesday. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. The company has a market cap of $28.51 billion, a price-to-earnings ratio of -155.38, a PEG ratio of 1.11 and a beta of 0.70. The business has a fifty day simple moving average of $20.60 and a 200-day simple moving average of $18.37. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $26.38.
- Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, November 5th. The company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.68 by $0.10. The firm had revenue of $4.48 billion for the quarter, compared to analysts' expectations of $4.36 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The firm's revenue for the quarter was up 3.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.69 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.550-2.650 EPS. On average, equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.
Insider Activity
In related news, Director Roberto Mignone sold 200,000 shares of the stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the completion of the sale, the director owned 495,000 shares of the company's stock, valued at approximately $11,934,450. This represents a 28.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.49% of the company's stock.
Analysts Set New Price Targets
- 2 Generic Drug Stocks Ready to Surge in 2025
Several analysts have commented on the stock. JPMorgan Chase & Co. lifted their target price on shares of Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the stock an "overweight" rating in a research note on Thursday, November 6th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a report on Saturday, October 11th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Finally, UBS Group increased their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a "buy" rating in a research report on Wednesday, September 24th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of "Buy" and an average price target of $25.86.
Read Our Latest Report on TEVA
Teva Pharmaceutical Industries Company Profile
(Free Report)Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
See Also
- Five stocks we like better than Teva Pharmaceutical Industries
- What is MarketRank™? How to Use it
- What’s on the Thanksgiving Table? A Stock Pick for Every Course
- How to Short Nasdaq: An Easy-to-Follow Guide
- Why Home Depot’s Pain Could Be a Long-Term Investor’s Gain
- 5 Top Rated Dividend Stocks to Consider
- Qualcomm’s Bulls Are Running Out of Room to Be Wrong
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Teva Pharmaceutical Industries Right Now?
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
